Gene therapies bring much-needed hope for treating rare conditions, but also concerns, especially around affordability. Learn about strategies plan sponsors can take to address these million-dollar me...

Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.

Recent research suggests that the number of gene therapies on the market is likely to increase to over 60 by 2030. As rapid advancements in the field continue, here is what plan sponsors can expect to...

We answer our clients’ burning questions about gene therapies, including how they work, whether or not they’re safe, and if we’ll see more in the future.

Gene modification and cellular therapies are unique, potentially curative treatments that leverage gene-altering technology

As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.

As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.

By supporting and encouraging evidence-based access to gene therapy, payers and other segments of U.S. society will be positioned to benefit from future advancements and biopharmaceutical breakthrough...

Breaking down the challenges, therapies and costs associated with hemophilia.